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Goal. Surgeons that remove a typical polyp from the stomach or small intestine should be reluctant to accept a diagnosis of GIST
just because there is a mutation in platelet-derived growth factor receptor alfa (PDGFRA). Background. A subtype of gastric and
intestinal polyps is denoted as inflammatory fibroid polyp (IFP). In some of these cases a mutation in PDGFRA is found, leading
to the diagnosis of gastrointestinal stromal tumor (GIST). Study. This study includes two patients that had polyps removed from
the ileum, and an extended investigation was performed with immunohistochemical staining and mutation analyses. Results. The
tumors did not show typical immunohistochemical staining for markers used to diagnose GIST, but the mutation analysis revealed
a mutation in PDGFRA exon 12. On the basis of the mutation analysis, both polyps were primarily diagnosed as GISTs, but the
diagnosis was later changed to inflammatory fibroid polyp.Conclusion. It is important that both surgeons and pathologists be aware
that IFP can harbor a mutation in PDGFRA where further treatment and follow-up is different with the two different diagnoses.
A mutation analysis can be misleading when taken out of the context of clinical observations, histological characteristics and
immunohistochemical staining.
1. Introduction
Gastric and intestinal polyps can broadly be defined as
luminal lesions projecting above the plane of the mucosal
surface. They are relatively frequent in routine pathology
practice, where the main goal is to rule out the possibil-
ity of malignancy. Various subtypes of gastric polyps are
recognized and generally divided into nonneoplastic and
neoplastic with the latter being defined as an abnormal
proliferation of cells with some degree ofmalignant potential.
In 1948 Vanek described gastric polyps that he termed
“submucosal granuloma with eosinophilic infiltration” [1].
Subsequently these polyps have had multiple names, but
the term inflammatory fibroid polyp (IFP) has gained wide
acceptance [2]. They are mostly found in the antrum/pyloric
area and in ileum [3, 4] and may be found incidentally
or during evaluation of gastric hemorrhage, anemia, or
symptoms of gastric outlet obstruction [5, 6]. Inflammatory
fibroid polyps are well-circumscribed, solitary, small sessile
or pedunculated lesions. The polyps usually do not reoccur
after resection and, therefore, local excision is an adequate
treatment [7, 8].
Histologically the polyps are centered in the submucosa
and characterized by the proliferation of small, thin-walled
blood vessels surrounded by a mesenchyme of short spindle
cells that may be arranged in an “onion-skin” pattern around
larger vessels. There are many inflammatory cells, often
dominated by eosinophils. Immunohistochemical evalua-
tions show that the tumors are variable and often CD34
positive but CD117 negative [4, 6].
Inflammatory fibroid polyps can harbor mutations in
the platelet-derived growth factor receptor alfa (PDGFRA)
gene, and this was first published by Schildhaus et al. [9]
and later also by Lasota et al. [4]. Such PDGFRA mutations
had previously only been found in gastrointestinal stromal
tumors (GISTs) [10].
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GISTs are the most common mesenchymal tumors of
the gastrointestinal tract most commonly found in the
stomach and small intestine [11]. Morphologically, they are
usually cellular tumors composed of spindle or epithelioid
cells but can show a wide variety of histological features.
Immunohistologically they are usually CD117, DOG1, and
CD34 positive with some cases staining for smooth muscle
actin, desmin, and S100 [12]. Gain-of-function mutations
have been found in the KIT gene (type III tyrosine kinase
family) or in the PDGFRA gene with the two of them being
practically mutually exclusive [10, 13]. The GISTs that show
mutations in PDGFRA are often CD117 negative and with
a dominant histological appearance of epithelioid-like cells.
It is often considered that molecular analyses are necessary
to confirm the diagnosis of GIST and to determine further
therapeutic strategy for these patients [14].
In this report we consider two cases primarily diagnosed
as probable GISTs after histological evaluation, where the
molecular analyses were performed to confirm the diagnosis
and for therapeutic strategy. A retrospective evaluation of
these two cases revealed that the mutational analyses used
to confirm the diagnosis of GIST are also applicable for
confirming the diagnosis of inflammatory fibroid polyp.
2. Materials and Methods
2.1. Cases. Patient number one was a woman in her late
thirties that received surgery because of invagination in the
ileum and with the discovery of a polyp. She had abdominal
pain two days prior to admittance to hospital. The resected
small intestine was 18.5 cm long and contained an almost
circular polyp with largest diameter 3.8 cm. At the base four
small wart-like lesions 0.2–0.5 cm in diameter were found.
The lesion was resected with free margins. She had a CT scan
12months after her operationwithout any evidence of relapse,
and at the clinical consultation she was in good health.
Patient number two was a man in his late forties with
a polyp in the distal ileum. Prior to his operation he had
complained of abdominal pain for 7 months. He too was
operated because of invagination. The pathologist received
14 cm of small intestine with a freely resected 5 cm long
polyp that was 1.4 cm in diameter at the base. The patient
did not have any further surgery and did not receive any
additional medication. He experienced some nausea a couple
of months after the operation, but at control after 5 months
he felt healthy. A CT scan at this point did not reveal any
pathological features.
2.2. Immunohistochemical Staining. Both cases were evalu-
ated on hematoxylin and eosin stain and in addition were
stained immunohistochemically with CD117, DOG1, CD34,
ki67, CD45, S100, desmin, and smooth muscle actin. The
staining was evaluated independently by two senior pathol-
ogists (BB and SES).
2.3. Mutational Analyses. For DNA isolation, the lesional
areas were marked on a hematoxylin and eosin (H&E) slide
by a senior pathologist. The slides were used as a guide to
orient the formalin-fixed, paraffin-embedded (FFPE) tissue
block, and tumor tissue was selected from the block by a
scalpel. Paraffin was removed with xylene, and total DNA
was isolated using QIAamp DNA mini kit (Qiagen GmbH,
Hilden, Germany). Selected parts of KIT exon 9, 11, 13, and
17 and PDGFRA exon 12 and 18 were amplified by PCR.
Primer sequences have been published previously [13], except
for primer sequences for KIT exon 13 and 17. These exons
were amplified using the following intronic primer pairs
(listed 5󸀠 to 3󸀠): exon 13F ATGCGCTTGACATCAGTTTG;
exon 13R CATGTTTTGATAACCTGACAGACA; exon 17F
GGTTTTCTTTTCTCCTCCAACC; exon 17R TGAAAC-
TAAAAATCCTTTGCAGG. The annealing temperature for
all sets of primers was 55∘C.The PCR products were analyzed
by direct sequencing using a BigDye Terminator (Applied
Biosystems, Foster City, CA, USA) and run on an ABI
3130 Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA). All PCR products were sequenced on both strands. In
addition the PCRproducts ofKIT exon 9 and 11 andPDGFRA
exon 12 and 18 were analyzed by capillary electrophoresis
using the ABI 3130 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA) to target insertions or deletions in
these exons. The nomenclature of the mutations is based on
the recommendations of Human Genome Mutation Soci-
ety (http://www.hgvs.org/mutnomen/). The KIT sequence
(NM 000222.1) and the PDGFRA sequence (NM 006206)
obtained from the National Centre for Biotechnology Infor-
mation (NCBI) at http://www.ncbi.nlm.nih.gov/ were used as
reference sequences.
3. Results
3.1. Histology and Immunohistochemistry. Both tumors had
an equal histological appearance with many small vessels and
a loose stroma with many inflammatory cells. Many of these
were eosinophilic granulocytes. The stroma was negative for
the GIST markers CD117 and DOG1 and the neuroderived
marker S100. The mesenchymal marker CD34 was negative,
but there was a weak stain with smoothmuscle actin. Desmin
was only positive in the vessel walls. CD45 was positive
in inflammatory cells. The proliferation marker Ki67 was
positive in around 10% of the tumor cells.
3.2. Mutation Analysis
Patient one: c.1696 1711del
(p.Ser566 Glu571delinsLys)
Patient two: c.1696 1713delinsCGC
(p.Ser566 Glu571delinsArg) Figure 1.
4. Discussion
IFP is a benign neoplasm that should not be mistaken for a
GIST.The treatment of IFP is surgery only, and fully resected
polyps hardly reoccur. Gastrointestinal stromal tumors differ
from the IFP by having a malignancy potential even at small
size and lesions arising in the small bowel are graded as more
aggressive than those found in the stomach [15].
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Figure 1: Capillary electrophoresis ((a) and (c)) and direct sequencing ((b) and (d)) of PDGFRA exon 12 from patient numbers one and two.
Red rings indicate mutated alleles; green rings indicate normal alleles. Black boxes indicate amino acids deleted in the mutated alleles.
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Clinically the IFP is an intraluminal polyp in the stomach
or small intestine and is often simply regarded by the surgeon
as a polyp. The GIST arises from the cells of Cajal in the
intramuscular part of the GI-wall and is mostly found as
a tumor under the mucosa. The histological picture of the
IFP reveals a tumor with plenty of small vessels surrounded
by loose mesenchyme containing a prominent inflammatory
infiltrate. Many of the inflammatory cells are eosinophilic
granulocytes. The GIST is in most cases composed of spindle
cells arranged in fascicles or sheets but can also reveal more
epithelioid features. They can be highly vascularized, but
mostly they have small and inconspicuous vessels. Some cases
have quite a few inflammatory cells, but mostly they contain
only scattered lymphocytes. Immunohistochemically, IFPs
are variably positive for CD34 and negative for CD117 and
DOG1, while GISTs are almost always positive for CD117,
DOG1, and CD34. Both tumors are mostly negative for actin,
desmin, and S100. Based on this, the diagnosis seems to be
quite straight forward, but sometimes the question of GIST
is raised even if the clinical information, histology, or the
immunohistochemical staining does not indicate this. This is
based on the fact that GIST can displaymany different clinical
and histological patterns, and a mutation in KIT or PDGFRA
is believed to confirm the diagnosis.
Approximately 10% of GISTs are wild type, and without
a mutation the diagnosis of GIST relies on expression of
immunohistochemical markers. In around 90% of the GISTs
a mutation in KIT or PDGFRA is found. A mutation in
PGDFRA exon 12 is very rarely found in GISTs, with an
incidence of around 2% [13]. Lasota et al. found, however,
mutations in PDGFRA 12 and 18 in 55% of 60 investigated
inflammatory fibroid polyps, with more than 90% of these
being in PDGFRA 12 [4].
The presented two cases in ileum did not have typical
histopathological features or immunohistochemical staining
expression patterns typical for GIST, but the clinicians had
raised the question about GIST. To reassure them and
ourselves that the patients had received the right diagnosis,
mutation analyses were performed. On the base of the
mutation analyses of the first case we concluded, reassuringly,
that the diagnosis of GIST was correct. When case two
came, sometime later, and also had this rare mutation in
PDGFRA exon 12, the diagnosis was not so obvious anymore.
A literature search revealed that IFP can harbor just such
mutations, and both diagnoses were later revised from GIST
to IFP.
The clinicians removed a polyp and did not question the
diagnosis of GIST after the pathologist had supplemented the
analysis with a convincing mutation analysis. The patholo-
gists were puzzled by the histopathological appearance, but
the mutation analyses were unmistakable. We were all fooled
to believe that the two cases were GISTs on the basis of the
PDGFRA exon 12 mutation. Technological progress can be
of invaluable help but can also create confusion and lead to
wrong conclusions when results are misinterpreted. A com-
bination of clinical information, histopathological features,
immunohistochemical staining, and molecular analyses is
essential for making the correct diagnosis.
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mann, and S. Merkelbach-Bruse, “Inflammatory fibroid polyps
harbour mutations in the platelet-derived growth factor recep-
tor alpha (PDGFRA) gene,” Journal of Pathology, vol. 216, no. 2,
pp. 176–182, 2008.
[10] M. C. Heinrich, C. L. Corless, A. Duensing et al., “PDGFRA
activating mutations in gastrointestinal stromal tumors,” Sci-
ence, vol. 299, no. 5607, pp. 708–710, 2003.
[11] M. Miettinen and J. Lasota, “Gastrointestinal stromal tumors
(GISTs): definition, occurrence, pathology, differential diagno-
sis and molecular genetics,” Polish Journal of Pathology, vol. 54,
no. 1, pp. 3–24, 2003.
[12] S. E. Steigen and T. J. Eide, “Trends in incidence and survival of
mesenchymal neoplasm of the digestive tract within a defined
population ofNorthernNorway,”APMIS, vol. 114, no. 3, pp. 192–
200, 2006.
[13] S. E. Steigen, T. J. Eide, B. Wasag, J. Lasota, and M. Miettinen,
“Mutations in gastrointestinal stromal tumors—a population-
based study from northern Norway,” APMIS, vol. 115, no. 4, pp.
289–298, 2007.
Case Reports in Medicine 5
[14] H. Yamamoto, A. Kojima, S. Nagata, Y. Tomita, S. Takahashi,
and Y. Oda, “KIT-negative gastrointestinal stromal tumor of the
abdominal soft tissue: a clinicopathologic and genetic study of
10 cases,” American Journal of Surgical Pathology, vol. 35, no. 9,
pp. 1287–1295, 2011.
[15] H. Joensuu, A. Vehtari, J. Riihimäki et al., “Risk of recurrence
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